期刊文献+

ADC值评价骨肉瘤新辅助化疗后坏死的价值 被引量:7

The value of ADC in determining osteosarcoma necrosis after neoadjuvant chemotherapy
在线阅读 下载PDF
导出
摘要 目的:通过病理学对照研究,探讨ADC值评价骨肉瘤新辅助化疗后坏死的价值。方法:12例行新辅助化疗的原发四肢骨肉瘤患者,在其完成新辅助化疗后且手术前3天内同时行常规MRI和DWI检查。参照MRI和ADC图表现,在术后大体标本相应区取材,获取骨外软组织肿块127个区,分析不同ADC值的病理基础。结果:非软骨性肿瘤存活区、软骨性肿瘤存活区、非软骨性肿瘤坏死区、肿瘤坏死后胶原化区、肿瘤坏死囊变血腔及继发动脉瘤样骨囊肿区ADC值分别约(1219.63±26.73)×10-6 mm2/s、(2193.21±37.87)×10-6 mm2/s、(1770.52±33.41)×10-6 mm2/s、(2287.36±39.34)×10-6 mm2/s和(2293.57±50.36)×10-6 mm2/s。非软骨性肿瘤存活区与其它4区、非软骨性肿瘤坏死区与其它4区ADC值之间差异均有统计学意义(P<0.001),软骨性肿瘤存活区、肿瘤坏死后胶原化区、肿瘤坏死囊变血腔及继发动脉瘤样骨囊肿区ADC值之间差异均无统计学意义(P>0.05)。结论:ADC值在判定骨肉瘤化疗后坏死时,会受到存活的软骨性肿瘤成分的影响;借助ADC值可鉴别骨肉瘤化疗后非软骨性肿瘤细胞的存活、坏死和瘤细胞外间质改变。 Objective:To study the value of ADC in determining osteosarcoma necrosis after neoadjuvant chemotherapy.Methods:12 patients with histologically proven primary limb bone osteosarcoma all underwent MRI and DWI scanning after neoadjuvant chemotherapy and three days before limb resection.A comparative study between histopathologic findings and DWI features was performed in 127 specimens from soft-tissue mass around affected bone in order to investigate histopathologic features of different ADC regions.Results:The mean ADC values in non-cartilaginous tumor survival region,cartilaginous tumor survival region,non-cartilaginous tumor necrosis region,tumor post-necrosis collagen region,cystic necrosis hemocoele and secondary aneurysmal bone cysts region were(1219.63±26.73)×10-6,(2193.21±37.87)×10-6,(1770.52±33.41)×10-6,(2287.36±39.34)×10-6 and(2293.57±50.36)×10-6mm2/s,respectively.The difference in ADC was statistically significant(P0.001) between the non-cartilaginous tumor survival region and the other four regions,also between the non-cartilaginous tumor necrosis region and the other four regions,but the difference in ADC was not statistically significant(P0.05) among the cartilaginous tumor survival region,tumor post-necrosis collagen,cystic necrosis,hemocoele and secondary ABC region.Conclusion:ADC value may be affected by the living cartilaginous tumor elements in the judgement of osteosarcoma necrosis after neoadjuvant chemotherapy.ADC value can determine non-cartilaginous tumor living cells,necrotic cells and extra-cell interstitial tissue changes.
出处 《放射学实践》 2012年第5期540-544,共5页 Radiologic Practice
基金 广东省科技计划项目资助(2011B031800096)
关键词 骨肉瘤 抗肿瘤联合化疗方案 磁共振成像 Osteosarcoma Antineoplastic combined chemotherapy protocols Magnetic resonance imaging
  • 相关文献

参考文献10

  • 1Bielack S,Carrle D,Casali PG.Osteosarcoma:ESMO clinical rec-ommendations for diagnosis,treatment and follow-up[J].Ann On-col,2009,20(Suppl 4):S137-S139.
  • 2Provisor AJ,Ettinger LJ,Nachman JB,et al.Treatment of non-metastatic osteosarcoma of the extremity with preoperative andpostoperative chemotherapy:a report from the Children′s CancerGroup[J].J Clin Oncol,1997,15(1):76-84.
  • 3Bramer JA,van Linge JH,Grimer RJ,et al.Prognostic factors inlocalized extremity osteosarcoma:a systematic review[J].Eur JSurg Oncol,2009,35(10):1030-1036.
  • 4Rosen G,Caparros B,Huvos AG,et al.Preoperative chemothera-py for osteogenic sarcoma:selection of postoperative adjuvantchemotherapy based on the response of the primary tumor to pre-operative chemotherapy[J].Cancer,1982,49(6):1221-1230.
  • 5Hayashida Y,Yakushiji T,Awai K,et al.Monitoring therapeuticresponses of primary bone tumors by diffusion-weighted image:in-itial results[J].Eur Radiol,2006,16(12):2637-2643.
  • 6Uhl M,Saueressig U,Koehler G,et al.Evaluation of tumour nec-rosis during chemotherapy with diffusion-weighted MR imaging:preliminary results in osteosarcomas[J].Pediatr Radiol,2006,36(12):1306-1311.
  • 7孟悛非,马玲,陈应明,江波.EPI-DWI-ADC图对确定恶性骨肿瘤髓内浸润范围的价值[J].中国CT和MRI杂志,2003,1(1):46-51. 被引量:5
  • 8马玲,孟悛非,陈应明,江波.表观扩散系数值在原发性恶性骨肿瘤诊断中的价值[J].中华放射学杂志,2004,38(11):1129-1134. 被引量:20
  • 9程克斌,张晶,宫丽华,屈辉,张薇,梁伟,李晓松,程晓光.含软骨基质型肉瘤的MR钆喷替酸葡甲胺增强和扩散加权成像特点[J].中华放射学杂志,2010,44(6):635-638. 被引量:2
  • 10马婉玲,徐俊卿,葛雅丽,韩月东,印弘,魏光全,刘莹,常英娟,赵海涛,宦怡.骨肉瘤的MRI及DWI表现[J].实用放射学杂志,2008,24(4):516-518. 被引量:6

二级参考文献45

  • 1孙燕萍,李四君,郭卫,蒋全胜,刘涛.软骨母细胞型骨肉瘤的MRI增强形式与组织病理学的相关性研究[J].中国医学影像技术,2005,21(2):301-303. 被引量:4
  • 2De Baere T, Vanel D, Shapeero LG,et al. Osteosarcoma after chemotherapy: evaluation with contrast material enhanced subtraction MR imaging[J]. Radiology, 1992.185(2) :587 - 592.
  • 3Provenzale JM, Sorensen AG. Diffusion- weighted MR imaging in acute stroke - theoretic considerations and clinical applications (Review)[J]. AJR, 1999.173,(6) :1459- 1467.
  • 4Baur A. Reister MF. Diffusion - weighted imaging of the musculoskeletal system in humans[J]. Skeletal Radiol, 2000,29(10) :555 - 562.
  • 5Herneth AM, Philipp MO,Naude J, et al. Yertebral metastases:assessment with apparent diffusion coefficient [J]. Radiology ,2002,225(3) :889 - 894.
  • 6Vande Berg BC, Malghem J, Lecouvet FE, et al. Magnetic resonance imaging of the normal bone marrow [ J ]. Skeletal Radiol, 1998,27 (9) :471 -483.
  • 7Hayashida Y,Yakushiji T,Awai K, et al. Monitoring therapeutic responses of primary bone tumors by diffusion- weighted image: initial results [J]. Eur Radiol, 2006,16 ( 12 ) :2637 - 2643.
  • 8Kim YJ, Chang KH, Song IC, et al. Brain abscesses and necrotic or cystic brain tumor: discrimination with signal intensity on diffusion - weighted MR imaging[J]. AJR, 1998,171 (6) : 1487 - 1490.
  • 9Sugahara T, Korogi Y, Kochi M, et al . Usefulness of diffusion - weighted MRI with echo - planar technique in the evaluation of cellularity in gliomas[J]. J Magn Reson Imaging, 1999 ; 9 ( 1 ) :53 - 60.
  • 10Baur A, Dietrich O, Reiser M, et al. Diffusion - weighted imaging of bone marrow : current status [ J ]. Eur Radiol, 2003,13 (7) : 1699 - 1708.

共引文献29

同被引文献57

  • 1马玲,孟悛非,陈应明,江波.表观扩散系数值在原发性恶性骨肿瘤诊断中的价值[J].中华放射学杂志,2004,38(11):1129-1134. 被引量:20
  • 2董岩青,李坤成,尹建国.骨肉瘤病的影像学表现——附1例报道及文献复习[J].罕少疾病杂志,2000,7(1):21-23. 被引量:5
  • 3郭全义,卢世璧,张莉,眭翔,田玥,许文静,孙明学.骨肉瘤的治疗及生存率的多因素分析[J].中国矫形外科杂志,2006,14(7):497-499. 被引量:13
  • 4Kudawara I, Aoki Y, Ueda T, et al. Neoadjuvant and adjuvantchemotherapy with high-dose ifosfamide, doxorubicin, cisplatin and high-dose methotrexate in non-metastatic osteosarcoma of the extremities: A phase II trial in Japan. J Chemother, 2013, 25 (1) :41-48.
  • 5Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: Noninvasive in vivo assessment of tumor necrosis with diffusion- weighted MR imaging. Radiology, 1998,206 (1) : 227-235.
  • 6Gareia-Castellano JM, Atallah YN, Reyes C, et al. Histopatho- logic and radiologic assessment of chemotherapeutic response in e- wing's sarcoma: A review. Sarcoma, 2012,2012 : 357424.
  • 7Fayad LM, Jacobs MA, Wang X, et al. Musculoskeletal tumors: How to use anatomic, functional, and metabolic MR techniques. Radiology, 2012,265(2) :a40-a56.
  • 8Oka K, Yakushiji T, Sato H, et al. The value of diffusion- weighted imaging for monitoring the chemotherapeutic response of osteusareoma: A comparison between average apparent diffu- sion coefficient and minimum apparent diffusion coefficient. Skeletal Radiol, 2010,39(2) : 141-146.
  • 9Uhl M,Saueressig U,Koehler G,et al. Evaluation of tumour necrosisduring chemotherapy with diffusion-weighted MR imaging :preliminary results in osteosarcomas. Pediatr Radiol, 2006,36:1306-1311.
  • 10Ross BD, Moffat BA, Lawrence TS, et al. Evaluation of cancer therapyusing diffusion magnetic resonance imaging. Mol Cancer Ther, 2003,2:581-587.

引证文献7

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部